AI Maverick Intel Inc. (OTC: AIMV) announced the issuance of 76.5 million common shares to HEAL Group Holdings as the initial tranche of consideration under the companies' Right of First Refusal Agreement dated Feb. 11, 2026, as AIMV advances its proposed acquisition of HEAL Access Canada Inc. The company said the total consideration tied to the transaction has been adjusted from 120 million to 100 million AIMV common shares, with the parties continuing toward a definitive agreement, while also noting plans to pursue an uplisting to the OTCQB Venture Market as part of its broader capital markets strategy.
The issuance of these shares marks a significant step forward in the acquisition process, which positions AI Maverick Intel to expand its footprint in the healthcare technology sector through HEAL Access Canada. The adjustment in total consideration reflects ongoing negotiations and due diligence, aligning the interests of both parties as they move toward a definitive agreement. The planned uplisting to the OTCQB Venture Market is expected to enhance the company's visibility and liquidity, potentially attracting a broader base of investors seeking opportunities in the artificial intelligence and data platform space.
AI Maverick Intel focuses on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The company evaluates strategic acquisitions, partnerships, and scalable platforms designed to drive long-term shareholder value. The proposed acquisition of HEAL Access Canada aligns with this strategy, offering a platform to leverage AI in healthcare access and data management.
Investors can find the latest news and updates relating to AIMV in the company's newsroom at http://ibn.fm/AIMV. For more details on the initial share issuance and the Right of First Refusal Agreement, the full press release is available at https://ibn.fm/mivWz.
This development underscores AI Maverick Intel's commitment to executing its growth strategy through strategic acquisitions and capital market initiatives. The successful completion of the HEAL Access Canada acquisition and the OTCQB uplisting could serve as catalysts for the company's valuation and market positioning. However, as with any forward-looking statements, actual results may vary based on market conditions and regulatory approvals.